EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation

scientific article published on 15 August 2006

EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1182/BLOOD-2006-04-013805
P698PubMed publication ID16912224

P50authorJorge Eduardo CortesQ60320900
Hagop KantarjianQ60394812
Francis J GilesQ62066745
Srdan VerstovsekQ64026418
Ayalew TefferiQ66370740
Taghi ManshouriQ91467065
P2093author name stringAlfonso Quintás-Cardama
Cem Akin
Jingxuan Pan
Peter Lamb
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectmast cellQ191989
P304page(s)315-322
P577publication date2006-08-15
P1433published inBloodQ885070
P1476titleEXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation
P478volume109

Reverse relations

cites work (P2860)
Q39993475Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies
Q37892475Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis
Q34786462Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells
Q37728667Aspirin inhibits proliferation of gemcitabine-resistant human pancreatic cancer cells and augments gemcitabine-induced cytotoxicity
Q37216023Concurrent inhibition of kit- and FcepsilonRI-mediated signaling: coordinated suppression of mast cell activation
Q38370943Current treatment options in patients with mastocytosis: status in 2015 and future perspectives
Q36059702Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells
Q54566864Diffuse cutaneous mastocytosis masquerading as epidermolysis bullosa.
Q37200035Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition
Q39149681Everolimus enhances the cytotoxicity of bendamustine in multiple myeloma cells through a network of pro-apoptotic and cell-cycle-progression regulatory proteins
Q35229969MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells
Q24313261Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells
Q37379320Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.
Q41939033Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice
Q39112113Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPARγ and RXRα.
Q35047163PQJS380: a novel lead compound to induce apoptosis in acute lymphoblastic leukemia cells
Q36842503Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders
Q26748784Pharmacological treatment options for mast cell activation disease
Q37591364Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin.
Q59810100Preclinical human models and emerging therapeutics for advanced systemic mastocytosis
Q33944952Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl
Q39244862Proteasome inhibition upregulates Bim and induces caspase-3-dependent apoptosis in human mast cells expressing the Kit D816V mutation
Q33911230SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.
Q39648444Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia
Q53343173Targeted therapy in KITD816V-positive mastocytosis: waiting for proof-of-principle.
Q40114178The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation
Q51048652The artemisinin derivative artesunate inhibits corneal neovascularization by inducing ROS-dependent apoptosis in vascular endothelial cells.
Q53553773The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
Q24306212Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors
Q34293285Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens.

Search more.